-

Ataraxis AI to Present Eight Studies at SABCS 2025 Expanding Clinical Utility of Ataraxis™ Breast

NEW YORK--(BUSINESS WIRE)--Ataraxis AI, an AI precision medicine company and frontier artificial intelligence (AI) research lab developing AI-powered tools for oncology, announced today that it will present eight research abstracts with Ataraxis™ Breast data at the 2025 San Antonio Breast Cancer Symposium (SABCS). Research to be presented by Ataraxis and its collaborators include extensive real-world validation of Ataraxis Breast RISK and head-to-head comparisons to the previous generation of tests, highlighting the expanding clinical utility of Ataraxis tools. Ataraxis will also present first-ever data on Ataraxis Breast NEO, a test predicting response to neoadjuvant therapy, as well as results of research from the Ataraxis frontier AI research lab focused on the development of AI foundation models and calibration of prognostic models.

Poster Spotlight Presentation on December 12, 7:00 AM–8:30 AM CST

Poster Spotlight 11 (PD11-07): AI-Driven Risk Reclassification in HR+/HER2− Breast Cancer: Real-World Comparison with the 21-Gene Assay

  • Presenter: Elena Diana Chiru, MD (Cancer Center Baselland)

This spotlight presentation demonstrates how Ataraxis AI’s digital pathology model reclassifies recurrence risk in HR+/HER2− breast cancer compared to the 21-gene assay, using real-world data from European clinical cohorts.

Poster Presentations on December 10, 5:00 PM–6:30 PM CST

PS2-08-28: Artificial Intelligence-Based Histopathology Model Predicts Recurrence Risk in Older Patients with Early HR+/HER2− Breast Cancer: Results from the Basel University Hospital Cohort

  • Presenter: Elena Diana Chiru, MD (Cancer Center Baselland)

Poster Presentations on December 11, 12:30 PM–2:00 PM CST

Poster PS3-04-04: AI Predicts Response to Neoadjuvant Therapy in Breast Cancer Across Diverse Cohorts

  • Presenter: Frederick Howard, MD (UChicago Medicine)

Poster PS3-06-03: Refining Adjuvant CDK4/6 Inhibitor Eligibility in Early HR+ HER2- Breast Cancer with Artificial Intelligence

  • Presenter: Nicholas P. McAndrew, MD MSCE (University of California Los Angeles)

Poster PS3-06-06: A Comparison of Prognostic Predictors in Node-Positive HR+/HER2- Breast Cancer

  • Presenter: PD Dr. med. Marcus Vetter (Cantonal Hospital Baselland)

Poster PS3-06-07: Aligning AI Recurrence Predictions with Real-World Recurrence Rates Through Survival Calibration

  • Presenters: Krzysztof J. Geras, PhD (Ataraxis AI)

Poster PS3-06-10: Pan-cancer AI Foundation Models Yield Accurate Biomarker and Survival Predictions in Breast Cancer

  • Presenter: Krzysztof J. Geras, PhD (Ataraxis AI)

Poster PS3-06-17: Prognostic Performance Analysis of Artificial Intelligence Test and 21-Gene Assay in Premenopausal Node-Positive HR+/HER2- Breast Cancer Patients

  • Presenter: Jailan Elayoubi, MD (Karmanos Cancer Institute)

About Ataraxis AI

Ataraxis™ is an AI precision medicine company transforming patient outcomes through the power of artificial intelligence. Its flagship platform, Ataraxis Breast, leverages digital pathology and clinical data to support personalized treatment decisions for patients with breast cancer and provides greater accuracy than standard of care genomic assays. To learn more, visit ataraxis.ai

Contacts

Media: press@ataraxis.ai

Industry:

Ataraxis AI

Release Versions
English
Hashtags
#AIPrecisionMedicine
#AtaraxisAI
#AtaraxisBreast
#BreastCancer
#SABCS2025

Contacts

Media: press@ataraxis.ai

Social Media Profiles
Ataraxis AI on LinkedIn
Ataraxis AI on X
More News From Ataraxis AI

Ataraxis AI Publishes Landmark Studies Showing Causal AI Predicts Chemotherapy Benefit in Multiple Solid Tumors

NEW YORK--(BUSINESS WIRE)--Ataraxis AI, a company building clinical AI tools to personalize cancer care, today announced scientific breakthroughs and validation results of Ataraxis’s AI models. Ataraxis developed breakthrough causal AI methods that learn from large-scale, longitudinal data to predict patient outcomes in counterfactual treatment scenarios. These methods were encompassed in an AI world model called Ataraxis Tau. Ataraxis Tau was applied to breast cancer, developing a model simula...

Ataraxis AI Launches ARC, a Large-Scale Prospective Study Linking AI Model Predictions to Real Patient Outcomes Across Oncology

NEW YORK--(BUSINESS WIRE)--Ataraxis AI, a frontier clinical artificial intelligence (AI) company developing AI-powered tools for oncology, today announced the launch of Ataraxis ARC (the Ataraxis Real-World Clinical Outcomes Registry), a prospective, multi-site, observational study. ARC is a first-of-its-kind prospective study of AI-based tools in oncology, linking AI tool predictions with real-world short- and long-term patient outcomes.ARC will initially enroll approximately 1,000 patients acr...

Ataraxis AI's Laboratory Receives CAP Accreditation and California Clinical Laboratory License

NEW YORK--(BUSINESS WIRE)--Ataraxis AI, a frontier clinical artificial intelligence (AI) company developing AI-powered tools for oncology, today announced that its laboratory has received accreditation from the College of American Pathologists (CAP) and a clinical laboratory license from the State of California, expanding access to the Ataraxis Breast platform for clinicians and patients across the state.CAP accreditation follows an on-site inspection by practicing pathologists covering clinical...
Back to Newsroom